Autism spectrum disorder-like behaviors induced by hyper-glutamatergic NMDA receptor signaling through hypo-serotonergic 5-HT1A receptor signaling in the prefrontal cortex in mice exposed to prenatal valproic acid
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction. Here, we investigated the association between glutamatergic-serotonergic neuronal interactions and ASD-like behaviors in mice exposed to prenatal VPA. Prenatal VPA exposure induced excessive repetitive self-grooming behavior and impaired social behavior and object recognition memory in young adult period. Prenatal VPA mice showed hyper-glutamatergic function (increase in basal extracellular glutamate levels and CaMKII phosphorylation) and hypo-serotonergic function (decrease in 5-hydroxyindoleacetic acid and stimulation-induced serotonin [5-HT] release, but an increase in 5-HT transporter expression) in the prefrontal cortex. Treatment with a low-affinity NMDA receptor antagonist (memantine), a selective 5-HT reuptake inhibitor (fluoxetine), and a 5-HT<sub>1A</sub> receptor agonist (tandospirone) attenuated both the increase in CaMKII phosphorylation and ASD-like behavior of prenatal VPA mice. Opto-genetic activation of the serotonergic neuronal system attenuated impairments in social behavior and object recognition memory in prenatal VPA mice. WAY-100635-a 5-HT<sub>1A</sub> receptor antagonist-antagonized the effect of fluoxetine on impaired social behavior and object recognition memory. These results suggest that E/I imbalance and ASD-like behavior are associated with hypo-serotonergic receptor signaling through 5-HT<sub>1A</sub> receptors in prenatal VPA mice.
Authors
- Yoichi Hasegawa
- Akihiro Mouri (ORCID: https://orcid.org/0000-0003-3833-4041)
- Kazuo Kunisawa (ORCID: https://orcid.org/0000-0002-4786-9681)
- Hitomi Kurahashi
- Toshitaka Nabeshima (ORCID: https://orcid.org/0000-0001-5386-242X)
- Kenji F. Tanaka (ORCID: https://orcid.org/0000-0003-2511-0057)
- Hisayoshi Kubota (ORCID: https://orcid.org/0000-0002-0078-3418)
- M. Hasegawa (ORCID: https://orcid.org/0000-0003-1443-1082)
- Yuka Moriya
- Taku Nagai (ORCID: https://orcid.org/0000-0001-5050-7748)
- Kuniaki Saito (ORCID: https://orcid.org/0000-0001-5800-9305)
- Mai Miyachi
Institutions
- Fujita Health University (JP)
- Keio University (JP)
- Hokkaido Research Organization (JP)
- Meijo University (JP)
Publication Details
- Journal
- Neuropsychopharmacology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1038/s41386-024-02004-z
- Citations
- 8
- Primary Topic
- Autism Spectrum Disorder Research
- Type
- article
- Field-Weighted Citation Impact
- 2.74
Funders
- Takeda Science Foundation
- Smoking Research Foundation
- Fujita Health University
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency